An observational study in Colorectal Cancer, sponsored by Sohag University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Sohag University · Observational
Among 54 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 16 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.
Among the 54 studies in Colorectal Neoplasms with a site in Egypt, this one is the 15th largest by enrollment of the 22 observational ones that give a count, is one of 9 that started in 2022, is one of 22 observational ones, and was the 52nd registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 54 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ahmed Adel Ahmed Elsayed Ali Radwan · Sites in Egypt
Minia University · Sites in Egypt
Sohag University · Sites in Egypt
Sohag University · Sites in Egypt
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 13 · Phase 4 1
First in 1999; this study’s year is marked. 9 started in 2022.
This study's enrollment of 60 is below the median of 250 across 1,440 observational studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 31 interventional studies, 93 across the 22 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Sohag University has 9 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07736495Phase 3Ain Shams UniversityProtective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | 2026-12-27 |
| NCT07922642Alexandria UniversityNurse-Led Prehabilitation Before Major Abdominal Cancer Surgery | 2027-02-05 |
| NCT07144683Minia UniversityAnastomotic Leakage After Colorectal Surgery. | 2027-03-25 |
| NCT07874035Ahmed Adel Ahmed Elsayed Ali RadwanLow Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related Sarcopenia | 2027-08-15 |
| NCT07215936Sohag UniversityDose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | 2027-09 |
Among the 54 studies in Colorectal Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results.
Colorectal adenocarcinoma represents one third of human caners worldwide. It results from cumulative genetic mutations. the incidence of colorectal carcinoma is rising, so, detecting new therapeutic modalities is important. Wilms' Tumor 1 (WT1) gene is a tumor suppressor gene. in certain tumors; WT1 acts as an oncogene, facilitating tumor growth and spread. WT1 is also involved in angiogenesis. we decided to detect expression of WT1 in 60 patients with colorectal adenocarcinoma and detect any association between WT1 expression and certain tumor oarameters as perineural invasion, lymphovascular invasion, lymph node metastasis.
a retrospective, observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 formalin fixed, paraffin embedded tissue blocks belonged to patients with colorectal cancer. sections will be obtained and stained immunohistochemically with anti WT1 antibody.
Biological: immunohistochemical staining with WT1 antibody
4 micrometer thick tissue sections will be stained by anti humal WT1 immunohistochemical antibody.
detection of WT1 in colorectal adenocarcinoma
detection of WT1 in colorectal adenocarcinoma and correlate its expression in tumor cells with certain parameters as patients ages, sexes, tumor grade, lymph node metastasis, lymphovascular invasion and perineural invasion.
Time frame: 6 months
Plan to share: Undecided
Ran from Jan 2022 to primary completion in Dec 2025, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.